≤3 cm 非小细胞肺癌脏层胸膜侵犯的病理 T 分期修订建议
该回顾性研究纳入 1,055 例手术切除的 ≤3 cm 非小细胞肺癌(NSCLC),用弹性纤维染色重新判定脏层胸膜侵犯(VPI)程度。结果显示 PL1 与 PL0 的无病生存(DFS)和总生存(OS)均无显著差异,而 PL2 预后显著更差;作者据此建议 ≤3 cm NSCLC 的 PL1 仍归为 T1 而非 T2,以避免淋巴结阴性 PL1 患者接受过度辅助化疗。
要点
- ≤3 cm NSCLC 中 PL1 的 DFS 和 OS 与 PL0 相当,不应由 T1 上调为 T2。
- PL2 是独立不良预后因素,其 5 年 DFS 与 OS 显著低于 PL0 和 PL1。
- 淋巴结阴性、≤3 cm 的 PL1 患者或可避免辅助化疗过度治疗。
核心结论
- 在 ≤3 cm 的 NSCLC 中,PL1 肿瘤应仍定义为 T1 而非 T2。
- 淋巴结阴性、≤3 cm 的 PL1 病例或可避免辅助化疗造成的过度治疗。
研究设计与样本
- 回顾性纳入 1,055 例手术切除的 NSCLC 患者。
- 肿瘤切片经苏木精-伊红染色和维多利亚蓝弹性纤维染色重新判定弹性层受累情况。
- 采用 Kaplan-Meier 法计算 DFS 和 OS,并用亚组分析与 Cox 比例风险模型评估 VPI 对生存的影响。
主要发现
- VPI 程度诊断为 PL0 824 例、PL1 133 例、PL2 98 例。
- PL0、PL1、PL2 的 5 年 DFS 率分别为 62.6%、60.2%、28.8%(P < .01),5 年 OS 率分别为 78.6%、74.4%、50.0%(P < .01)。
- PL2 的 DFS 和 OS 显著差于 PL0(P < .01)和 PL1(P < .01),而 PL0 与 PL1 的 DFS(P = .198)和 OS(P = .150)相当。
- 淋巴结阴性病例中,PL0 与 PL1 的 DFS(P = .468)和 OS(P = .388)仍相当,PL2 则显著差于 PL0(P < .01)和 PL1(P < .01)。
- 多因素分析提示 PL2 与淋巴结阳性、细胞分化差同为独立不良预后因素。
关键数值与推荐
- ≤3 cm NSCLC 伴 PL1 仍归为 T1,不上调为 T2。
- 淋巴结阴性、≤3 cm 的 PL1 病例可考虑避免辅助化疗。
临床怎么用
- 对 ≤3 cm NSCLC 的 VPI 应区分 PL1 与 PL2,PL1 按 T1 管理。
- 淋巴结阴性 PL1 患者评估辅助化疗时应避免按 T2 过度治疗,PL2 患者需加强预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Visceral pleural invasion (VPI) with PL1 or PL2 increases the T classification from T1 to T2 in non-small cell lung cancers (NSCLCs) ≤ 3 cm. We proposed a modified T classification based on VPI to guide adjuvant therapy. RESEARCH QUESTION: Is it reasonable to upstage PL1-positive cases from T1 to T2 for NSCLCs ≤ 3 cm? STUDY DESIGN AND METHODS: In total, 1,055 patients with resected NSCLC were retrospectively included. Tumor sections were restained with hematoxylin and eosin stain and Victoria blue elastic stain for the elastic layer. Disease-free survival (DFS) and overall survival (OS) were calculated by the Kaplan-Meier method. Subgroup analysis and a Cox proportional hazards model were used to further determine the impact of VPI on survival. RESULTS: The extent of VPI was diagnosed as PL0 in 824 patients, PL1 in 133 patients, and PL2 in 98 patients. The 5-year DFS rates of patients with PL0, PL1, and PL2 were 62.6%, 60.2%, and 28.8% (P < .01), whereas the corresponding 5-year OS rates were 78.6%, 74.4%, and 50.0% (P < .01), respectively. As predicted, the DFS and OS of patients with PL2 were much worse than those of patients with PL0 (P < .01) and PL1 (P < .01). However, both the DFS and OS of patients with PL0 and PL1 were comparable (DFS: P = .198; OS: P = .150). For node-negative cases, the DFS and OS of patients with PL0 and PL1 were also comparable (DFS: P = .468; OS: P = .388), but patients with PL2 had much worse DFS and OS than patients with PL0 (P < .01) and PL1 (P < .01). Multivariable analyses suggested that PL2, together with node positivity and poor cell differentiation, was an independent adverse prognostic factor. INTERPRETATION: In NSCLCs ≤ 3 cm, tumors with PL1 should remain defined as T1, not T2. Overtreatment by adjuvant chemotherapy in node-negative NSCLCs ≤ 3 cm might be avoided in PL1 cases.
引用
- Liang RB, Li P, Li BT, et al. Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm. Chest. 2021. PMID: 33745993. doi:10.1016/j.chest.2021.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。